Human Umbilical Vein Endothelium-derived Cells Retain Potential to Differentiate into Smooth Muscle-like Cells*

Akira IshisakiDagger §, Hisaki HayashiDagger §, Ai-Jun LiDagger , and Toru ImamuraDagger ||

From the Dagger  Age Dimension Research Center, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8566, Japan and the  Institute of Biological Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8572, Japan

Received for publication, July 22, 2002, and in revised form, October 30, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mouse embryonic stem-derived cells were recently shown to differentiate into endothelial and smooth muscle cells. In the present study, we investigated whether human umbilical vein endothelium-derived cells retain the potential to differentiate into smooth muscle cells. Examination of biochemical markers, including basic calponin, SM22alpha , prostaglandin E synthase, von Willebrand factor, and PECAM-1, as well as cell contractility, showed that whereas endothelium-derived cells cultured with fibroblast growth factor can be characterized as endothelial cells, when deprived of fibroblast growth factor, a significant fraction differentiates into smooth muscle-like cells. Reapplication of fibroblast growth factor reversed this differentiation. Activin A was up-regulated in fibroblast growth factor-deprived, endothelium-derived cells; moreover, the inhibitory effects of exogenous follistatin and overexpressed Smad7 on smooth muscle-like differentiation confirmed that the differentiation was driven by activin A signaling. These findings indicate that when deprived of fibroblast growth factor, human umbilical vein endothelium-derived cells are capable of differentiating into smooth muscle-like cells through activin A-induced, Smad-dependent signaling, and that maintenance of the endothelial cell phenotype and differentiation into smooth muscle-like cells are reciprocally controlled by fibroblast growth factor-1 and activin A.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The progenitors of vascular endothelial cells (ECs)1 and smooth muscle cells (SMCs) have long been considered to be distinct from one another: ECs originate from angioblasts or hemangioblasts (1), whereas SMCs originate from neural crest and locally differentiating mesenchyme (2, 3). Fibroblast growth factors (FGFs) play key roles in the induction of both angioblasts (4) and hemangioblasts (4, 5) from mesoderm, and most endothelial precursors divide and differentiate in response to vascular endothelial growth factor (6, 7). At odds with this general view are several studies that suggest SMC-like cells can arise from atrio-ventricular and dorsal aorta ECs (8-11). For instance, transforming growth factor-beta 1 (TGF-beta 1) induced expression of smooth muscle alpha -actin (SM-alpha Actin) in bovine aortic ECs (8) and in mesenchymal cells (10). Furthermore, one recent study suggested that both ECs and SMCs develop from the same precursor: Flk1-expressing cells derived from embryonic stem cells (12). In this case, vascular endothelial growth factor promotes EC differentiation, whereas platelet-derived growth factor-BB promotes mural cell differentiation.

Normal ECs of human origin require the presence of an endothelial cell growth factor (e.g. FGF family members) in addition to serum for growth in culture (13, 14). In the present study, we examined the role of FGF in regulating the endothelial characteristics of human umbilical vein endothelium-derived cells (HUVE-DCs), also widely known as human umbilical vein ECs (HUVECs).

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- HUVE-DCs were isolated using the previously described method for isolating HUVECs (15). Human adult pulmonary artery endothelial cells (HPAECs) and human adult pulmonary artery smooth muscle cells (HPASMCs) were purchased from Kurabo Corp., Osaka, Japan. Recombinant human TGF-beta 1, activin A, bone morphogenetic protein (BMP)-4, and follistatin were from R&D Systems, Inc. (Minneapolis, MN). BQ123, BQ788, 8-bromo-cGMP, and endothelin-1 (ET-1) were from Calbiochem. Recombinant FGF-1 was expressed using the pET-3c system in BL21(DE3)pLysS cells and purified to homogeneity using heparin-Sepharose affinity chromatography as described previously (16). Heparin and anti-calponin monoclonal antibody (clone hCP) was from Sigma. Anti-von Willebrand factor (vWF) polyclonal antibody was from Dako. Anti-FLAG monoclonal antibody was from Eastman Kodak Co. Texas-Red-conjugated donkey anti-rabbit IgG and fluorescein isothiocyanate-conjugated sheep anti-mouse IgG were from Amersham Biosciences. Monoclonal anti-TGF-beta 1-, -beta 2-, -beta 3-neutralizing antibody was from Genzyme. Anti-Smad2 monoclonal antibody was from BD Transduction Laboratories. Antiserum PS2 recognizing the phosphorylated C-tail of Smad2 was generated, and its specificity was tested as described previously (17).

Cell Culture-- HUVE-DCs and HPAECs were plated in type I collagen-coated plastic culture dishes and maintained in M199 medium (Sigma) supplemented with 15% fetal bovine serum (Filtron) with or without 5 ng/ml FGF-1 plus 10 µg/ml heparin. The inclusion of heparin was for optimum FGF-1 activity; heparin exerted no effects on cell differentiation (data not shown). HPASMCs were cultured in HuMedia-SG2 (Kurabo Corp., Osaka, Japan) medium supplemented with 5% fetal calf serum, human epithelium growth factor (0.5 ng/ml), human FGF (2 ng/ml), insulin (5 µg/ml), gentamycin (50 µg/ml), and amphotericin B (50 ng/ml). For analysis of HPASMC contraction, cells were transferred to FGF-1- and heparin-free M199 medium supplemented with 15% fetal bovine serum and maintained for 2 weeks. After this period, the cells were plated on collagen type I gels and subjected to contraction analysis.

Immunocytochemical Study-- Cells were double-labeled with polyclonal anti-vWF and monoclonal anti-calponin primary antibodies and then secondarily labeled with Texas Red-conjugated donkey anti-rabbit IgG and fluorescein isothiocyanate-conjugated sheep anti-mouse IgG, respectively. The signals were then detected using a confocal laser scanning microscope (Carl Zeiss, Jena, Germany).

Adenovirus Vectors-- A recombinant E1-deleted adenoviral vector carrying mouse Smad7 cDNA ligated with FLAG-epitope (18) under the control of cytomegalovirus promoters was generated (AdCMV-Smad7) and purified as described previously (19, 20).

Semiquantitative Analysis of mRNA Expression-- Semiquantitative RT-PCR/Southern blot analysis was carried out as described previously (21). Briefly, total RNA was isolated from cells using Isogen (Nippon Gene), after which a 1-µg sample was reverse-transcribed using M-MLV reverse transcriptase (Invitrogen) according to the manufacturer's instructions. Using 4% of the reverse-transcribed mix, cDNA fragments of test genes were amplified within the linear range by PCR using AmpliTaq Gold (PerkinElmer Applied Biosynthesis). The specific primers used are listed in Table I. Aliquots of the PCR products were resolved on 1.0% agarose gels and transferred to Hybond N+ membranes (Amersham Biosciences). The membranes were then hybridized with the corresponding cDNA probe labeled with digoxygenin-labeled dUTP (DIG-High Prime, Roche Molecular Biochemicals). The signals were visualized, incorporated, and quantitated using NIH Image software (version 1.62).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Sequences of primers used in RT-PCR

Immunoblot Analysis-- The cells were lysed in lysis buffer (1% Triton® X-100, 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1× protease inhibitor mixture, CompleteTM (EDTA-free); Roche Molecular Biochemicals), and the extracted proteins (60 µg) were resolved by SDS-PAGE and electroblotted to polyvinylidene fluoride membranes (Millipore Corp., Bedford MA). The proteins of interest were then detected using appropriate antibodies and an ECL Western blotting detection system (Amersham Biosciences).

Cell Contraction Assay-- HUVE-DCs were first cultured with or without FGF-1 plus heparin for 3 weeks on type I collagen-coated plastic culture dishes, after which they were relaxed by incubation with 10 mM 8-bromo-cGMP for 20 min at 37 °C and embedded in collagen gels in 24-well plates (final concentration of 8-bromo-cGMP in the gel was 1 mM) (2.4 × 105 cells in 0.75 ml gel/well). The collagen gels were prepared using Cellmatrix type I-P (0.3% porcine type I collagen; Nitta-gelatin Corp., Osaka, Japan) following the manufacturer's instructions. Briefly, 10× M199 medium cell suspension in 1× M199 medium, bicarbonate buffer, fetal bovine serum, and Cellmatrix type I-P solution were combined at a ratio of 1:1:1:1.5:5.5, poured into wells, and allowed to polymerize. The resultant SMC-embedded gels were covered with 0.5 ml of M199 containing 15% fetal bovine serum. After incubating the gels for 17 h, by which time they had detached from the well bottoms, ET-1 (250 nM) was added to the culture once every 30 min. In some cases, ET-receptor (ET-R) antagonists (type A, BQ-123 (30 µM); type B, BQ-788 (10 µM)) were added to the culture for 30 min before application of ET-1. For quantification, each gel piece was transferred into a 1.5-ml micro-tube containing 500 µl of culture medium and then centrifuged, and its volume was measured. For morphological observation, relaxed differentiated cells were seeded onto precasted type I collagen gel (400 µl in 24-well plates) at a density of 4 × 104 cells/well, cultured for 17 h, and then treated with ET-1 and photographed under a phase-contrast microscope.

To compare the contractile capacity of differentiated HUVE-DCs and HPASMCs, relaxed cells were seeded onto precasted type I collagen gel (150 µl in 48-well plates) at a density of 2.8 × 104 cells/well. After incubating for 6 h, the cells were treated with 500 nM ET-1 for 25 min and then with 1 µM ET-1 for 5 min. Each gel was then carefully detached from the well wall and bottom, incubated for an additional 30 min in the same well, and then transferred onto a transparent plastic sheet. The degree of cell contraction was then determined by optically measuring the size of the cell sheets on the gel pieces.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Induction of SMC-like Cells from HUVE-DCs by Prolonged Deprivation of FGF-- We initially established a primary culture of HUVECs (HUVE-DCs) as described previously (15, 16). The cells were cultured in M199 medium supplemented with 15% serum, FGF-1, and heparin in collagen type I-coated flasks and were split 1:4 once every 3-4 days. Cells were always used for experimentation before they had reached 16 population doublings. As shown in Fig. 1a (left), the majority of cells appeared compact and uniform, and when cultured until confluent, they assumed the "cobble stone" appearance typical of ECs (not shown). Interestingly, when we removed FGF-1 and heparin from the growth medium for 3 weeks, an enlarged, flat cell type emerged (Fig. 1a, right). Immunostaining the cells for EC- and SMC-specific markers, i.e. vWF (22-25) and basic calponin (26-29), respectively, revealed that all cells maintained in FGF-1-containing medium were positive for anti-vWF antibody (red) and negative for anti-basic calponin (Fig. 1b, left), but a significant fraction of the FGF-1-deprived cells (9.4 ± 3.0% in number; n = 8) were positive for anti-basic calponin antibody (green), a marker of SMCs (Fig. 1b, right). We then examined the expression of several SMC- and EC-specific marker genes in FGF-deprived HUVE-DC cultures using RT-PCR combined with Southern blot analysis (Fig. 1c). mRNA expression of all the SMC marker genes examined, i.e. basic calponin, SM22alpha (30, 31), and prostaglandin E synthase (32), was clearly enhanced; indeed, expression of basic calponin and SM22alpha increased up to 50-fold during the 4-week period of FGF deprivation. Notably, expression of vWF mRNA was also increased in FGF-deprived cells after 1 week but had returned to its original level within 4 week. On the other hand, expression of another endothelial-specific gene, pecam-1 (12), was little changed.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 1.   HUVE-DCs express SMC markers after prolonged FGF-1 deprivation. In a and b, HUVE-DCs were grown in medium 199 containing 15% fetal bovine serum with (+) FGF-1 (5 ng/ml) and heparin (10 µg/ml). For induction of differentiation, the FGF-1 and heparin were removed (-) from the medium, and the cells were cultured for 3 weeks. In a, cells were photographed under a phase-contrast microscope. In b, cells were immunostained for vWF (red) and basic calponin (green). The scale bar = 50 µm. In c, HUVE-DCs were cultured for the indicated periods in the absence of FGF-1 and heparin, after which expression of mRNAs encoding various SMC and EC markers was examined by semiquantitative RT-PCR/Southern blot analyses (left panels). The relative expression level of each mRNA was plotted after normalization with GAPDH expression (right panels). For SMC markers, the maximal level detected was defined as 100% expression; for EC markers, the initial level was defined as 100% expression.

The above results suggest that HUVE-DC cultures are composed of a heterogeneous population with respect to their potential to differentiate into SMC-like cells. To minimize this heterogeneity and exclude the possibility that SMCs may have contaminated the primary HUVE-DC cultures, we carried out a limiting dilution of HUVE-DC cultures in FGF-1-containing growth medium. After establishing 30 single-cell-derived populations, they were deprived of FGF. We found that in all of the cloned cell populations, cells deprived of FGF were initially positive only for vWF, but after a period of FGF deprivation, some began to express basic calponin, confirming that SMC-like cells can indeed differentiate from ECs (Fig. 2). We then classified the clones into two groups: slowly differentiating and rapidly differentiating. Among the slowly differentiating clones (e.g. CL1), which represented 6 of the 30 cultures, basic calponin-positive cells were not detected after 2 weeks of FGF deprivation (Fig. 2a, left) but did appear within 3 weeks (not shown). Among the rapidly differentiating clones (e.g. CL14), basic calponin-positive cells appeared comparatively quickly (Fig. 2a, right). After 2 weeks, approximately one-fifth of the cells (11-23%, as determined by immunostaining) expressed basic calponin (Fig. 2b, middle; open arrow). Most of the other cells (69-87%) expressed vWF (left, arrowhead), and a small fraction (0-8%) expressed both vWF and basic calponin (Fig. 2b, right, closed arrows).


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 2.   Cloned HUVE-DCs retain the potential to differentiate into and revert from SMC-like cells. HUVE-DCs were cloned by limiting dilution; shown are representative clones. CL1 is a slowly differentiating clone, and CL14 is a rapidly differentiating one. In a, the cells were cultured for 2 weeks in the absence of FGF-1 and heparin and immunostained for vWF (red) and basic calponin (green). The scale bar = 50 µm. In b, CL14 cells double-immunostained for vWF (left) and basic calponin (middle), along with the merged image (right). Some cells are positive only for vWF (arrowhead), some are positive only for basic calponin (open arrow), and some are positive for both markers (closed arrows). The scale bar = 20 µm. In c, cloned HUVE-DCs were cultured for the indicated periods in the absence of FGF-1 and heparin, and expression of basic calponin and vWF mRNA was examined by semiquantitative RT-PCR/Southern blot analyses (top). The relative expression level of calponin mRNA was plotted after normalization with GAPDH expression (bottom); the maximum level detected was defined as 100% expression. In d, CL14 cells were cultured for 4 days in the absence of FGF-1 and heparin and then for another 4 days (until day 8) in the same medium without (-) or with (+) FGF-1 and heparin. Expression of basic calponin and SM22alpha mRNA was then assessed by semiquantitative RT-PCR/Southern blot analyses as in panel c (inset).

Consistent with the immunohistochemistry, semiquantitative analysis using RT-PCR/Southern blot revealed that levels of basic calponin mRNA reached a maximum in CL14 cells after 2 weeks of FGF deprivation and in CL1 cells after 3 weeks of deprivation (Fig. 2c). Expression of another smooth muscle cell-specific marker, SM22alpha , followed a similar time course (data not shown). These effects of FGF deprivation proved to be reversible. In the experiment shown in Fig. 2d, FGF-1 deprivation increased expression of basic calponin and SM22alpha mRNA by day 4. However, addition of FGF-1 at that time reversed the increase, almost eliminating expression of basic calponin and SM22alpha mRNA by day 8. A similar reversal of SMC-like-differentiation by FGF was also observed in parental HUVE-DCs (data not shown). In addition, as in the parental HUVE-DC cultures (Fig. 1c), expression of vWF mRNA increased in both FGF-deprived CL1 and CL14 cells (Fig. 2c).

To further investigate the characteristics of cells expressing SMC markers, we next examined their responsiveness to ET-1, which is produced by endothelium (33) and acts via a smooth muscle-specific receptor (ET-R type A) to induce contraction. Although expression of ET-R type A mRNA was undetectable in HUVE-DCs cultured with FGF (Fig. 3a, week 0), it was abundantly expressed after 2-4 weeks of FGF deprivation (Fig. 3a). We observed a similar induction of ET-R type A in CL1 cells (data not shown). Interestingly, the level of ET-R type A expression in the rapidly differentiating CL14 cells was high even in the presence of FGF (data not shown) and did not change during the 4-week period of FGF deprivation.


View larger version (64K):
[in this window]
[in a new window]
 
Fig. 3.   ET-1-evoked contraction of HUVE-DC-derived SMC-like cells. In a, HUVE-DCs were cultured in the absence of FGF-1 and heparin and for the indicated periods, after which their expression of ET-receptor type A and ET-1 mRNA was examined by semiquantitative RT-PCR/Southern blot analyses (left panels). The relative levels of each mRNA were plotted after normalization with GAPDH expression (right panels). For ET-R type A, the maximum level was defined as 100% expression; for ET-1, the initial level was defined as 100% expression. In b, after depriving cells cultured on collagen-coated plastic plates of FGF-1 and heparin for 3 weeks, they were plated on gels formed of type I collagen and incubated with (middle and right) or without (left) ET-1 (250 nM) for 30 min. The cells in the right panel were exposed to ET-R inhibitors (30 µM of BQ123 and 10 µM of BQ788) for 10 min prior to application of ET-1. Phase-contrast micrographs are shown. The scale bar = 50 µm. In c, HUVE-DCs cultured in growth medium containing FGF-1 (F) or in FGF-free medium for 3 weeks (D) were harvested and embedded into gels formed of type I collagen. Their capacity to contract was analyzed by comparing the relative volumes of gels in which the cells were (+) or were not (-) treated with ET-1 (250 nM) for 3.5 h. *, p < 0.05; Student's t test. In d, HUVE-DCs cultured in FGF-free medium for 3 weeks were harvested, embedded into collagen gel, and analyzed for their capacity to contract as in panel c. ET-R inhibitors (30 µM of BQ123 and 10 µM of BQ788) were added to some cultures for 30 min prior to application of ET-1. *, p < 0.05; Student's t test. In e, HUVE-DCs and CL14 cells cultured in FGF-free medium for 3 weeks, or HPASMCs cultured in FGF-free medium, were plated on type I collagen gels. The cells were treated (+) or not treated (-) with ET-1, after which cell contraction was analyzed by measuring the size of the cell areas on the gels. *, p < 0.05; Student's t test.

To determine whether they were capable of contraction, SMC-like cells were induced by FGF-free medium for 3 weeks and then plated on collagen type I gels containing 1 mM 8-Br-cGMP, which relaxed the cells. After incubating the gels for 17 h, we examined the effects of ET-1 (250 nM). Whereas the control cells appeared flat and relaxed in the collagen gels (Fig. 3b, left), ET-1 caused the cells to contract and become more rounded in shape (Fig. 3b, middle). Measurement of the gel volumes showed that ET-1 treatment reduced the volume of gels made up with FGF-deprived cells to 79.9% of control (Fig. 3c, D) but had no effect on gels made up with FGF-treated cells (Fig. 3c, F). Pretreating the cells with specific ET-R type A and type B antagonists (30 µM BQ123 and 10 µM BQ788, respectively) inhibited both the ET-1-evoked change in morphology (Fig. 3b, right) and the gel shrinkage (Fig. 3d). Thus, sensitivity to ET-1 and cell contractility correlated with the emergence of SMC-like cells in culture.

To further characterize the HUVE-DC-derived SMC-like cells, their contractility was compared with that of pure HPASMCs. Because of the limited availability of the cells, contractility was analyzed by comparing ET-1-evoked changes in cell area on collagen gels using smaller numbers of cells than were used for the gel volume assay shown in Fig. 3d. HUVE-DCs and CL14 cells cultured in FGF-free medium for 3 weeks or HPASMCs cultured in FGF-free medium were harvested and plated on type I collagen gels containing 0.5 mM 8-Br-cGMP. After incubating the cells for 6 h, the areas occupied by cells treated (+) or not treated (-) with ET-1 were compared. We found that the area occupied by HPASMCs decreased to 50.4% of control upon exposure to ET-1, whereas the areas occupied by the differentiated HUVE-DCs and CL14 cells declined to 73.1 and 74.9% of control, respectively (Fig. 3e).

Activin A Signaling Is Activated in FGF-deprived HUVE-DCs and Is Responsible for the SMC-like Differentiation-- Earlier studies suggested that SMC-like cells arise from atrio-ventricular (8) and dorsal aorta ECs (10) after stimulation with exogenous polypeptide growth factors belonging to the TGF-beta family. Because both migrating and resting ECs reportedly express activin A, which inhibits endothelial cell proliferation (34), we examined expression of activin A and other genes related to activin A signaling (Fig. 4a). We determined that activin A expression in CL14 cells increased after FGF-1 deprivation and that reapplying FGF-1 to the cells reversed this up-regulation (Fig. 4a). The same results were obtained with parental cells (data not shown). Expression of mRNAs encoding activin-inducible inhibitors of activin signaling, i.e. follistatin (35-37) and Smad7 (18, 38-42), was also reversibly increased after FGF-1 deprivation (Fig. 4a), indicating that endogenous activin A signaling is activated in FGF-deprived cells.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 4.   Importance of activin A signaling in the differentiation of HUVE-DCs into SMC-like cells. In a, CL14 cells were cultured for 4 days in the absence of FGF-1 and heparin and then for another 4 days (until day 8) in the same medium without (-) or with (+) FGF-1 and heparin. Expression of activin A mRNA and its related genes was examined by semiquantitative RT-PCR/Southern blot analyses (left panels). Relative expression levels were plotted after normalization with GAPDH expression; the initial level was defined as 100% expression (right panel). In b, HUVE-DCs were cultured for 5 days with or without FGF-1. Follistatin (1 µg/ml) was added to half of the cultures without FGF-1 once every 12 h throughout the culture period. The expression of mRNAs encoding SMC and EC markers was examined by semiquantitative RT-PCR/Southern blot analyses. In c, HUVE-DCs were cultured for 7 days with or without FGF-1, with (+) or without (-) activin A (100 ng/ml). Expression of marker genes was examined as in panel b. In d, HUVE-DCs were cultured for 9 days without FGF-1 in the presence (left) or absence (right) of activin A (100 ng/ml). The cells were then double-immunostained for vWF (red) and basic calponin (green). The scale bar = 50 µm. In e, CL1 and CL14 cells were cultured for 4 days in the absence of FGF-1 and heparin and then for another 4 days (until day 8) in the same medium with (+) or without (-) FGF-1 and heparin. Expression of activin A mRNA was examined by semiquantitative RT-PCR/Southern blot analyses (left panels). Relative expression levels were plotted after normalization with GAPDH expression (right panel). In f, CL1 and CL14 cells were cultured for 7 days with or without FGF-1 in the presence or absence of activin A (100 ng/ml), after which marker gene expression was examined as in panel b.

To examine the role of activin A signaling in the induction of SMC-like differentiation, we first attempted to block the signaling by adding excess exogenous follistatin to the cultures. HUVE-DCs were cultured with or without FGF-1 for 5 days in the presence or absence of follistatin (1 µg/ml applied every 12 h) (Fig. 4b). Adding follistatin to the culture medium significantly diminished induction of basic calponin and SM22alpha expression (Fig. 4b), although it had no effect on vWF expression (Fig. 4b). This result strongly suggested that endogenous activin A signaling is responsible for inducing the SMC-like phenotype in FGF-deprived HUVE-DCs. Consistent with that interpretation, addition of exogenous activin A to FGF-deprived cultures induced expression of basic calponin and SM22alpha mRNA (Fig. 4c), as well as calponin protein (Fig. 4d). Interestingly, when we simultaneously added FGF-1, the activity of exogenous activin A was suppressed (Fig. 4c).

The importance of activin A signaling in the induction of SMC-like differentiation of HUVE-DCs was examined further by comparing expression of activin A in CL1 and CL14 cells, which, respectively, show low and high potentials for SMC-like differentiation (Fig. 2). Following FGF-1 deprivation, activin A expression rapidly increased in CL14 cells, reaching 775% of control (Fig. 4e, right panel). By contrast, activin A expression in CL1 cells increased only modestly, reaching 152 and 176% of control after 4 and 8 days of FGF-1 deprivation, respectively (Fig. 4e, right panel). We also examined the effect of exogenously applied activin A on cell differentiation and found that, in the absence of FGF, exogenous activin A induced expression of basic calponin and SM22alpha mRNA in both CL1 and CL14 cells but to a much greater extent in the latter (Fig. 4f). Thus, activin A signaling appears to correlate with SMC-like differentiation of HUVE-DCs at the cell population level, suggesting that such differentiation is determined, at least in part, by the level of activin A expression following FGF deprivation.

We also attempted to block activin A signaling by overexpressing an inhibitory Smad in HUVE-DCs. Because HUVE-DCs are difficult to transfect using typical expression vectors, we infected the cells with AdCMV-Smad7, an adenoviral vector carrying mouse Smad7. As expected, the level of Smad7 expression was dependent on the vector dosage (Fig. 5a). Transfection with Smad7 significantly diminished positive Smad signaling in HUVE-DCs: it inhibited both the activin A-induced phosphorylation of Smad2 (Fig. 5b) and its nuclear translocation (38-41) (Fig. 5c). In addition, control cells, but not Smad7 transfectants, underwent SMC-like differentiation when FGF-deprived and thus showed increased expression of basic calponin and SM22alpha mRNAs (Fig. 5d) and of basic calponin protein (green) (Fig. 5e). There was no difference in the level of vWF mRNA expression in control and Smad7-overexpressing cells.


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 5.   Inhibition of HUVE-DC differentiation into SMC-like cells by overexpression of Smad7. a, expression of FLAG-Smad7 in HUVE-DCs infected with various amounts of AdCMV-FLAG-Smad7. The cells were then lysed, and expression of the target protein was analyzed by immunoblotting. AdCMV-LacZ was used in control experiments. b, activation of Smad2 by activin A. HUVE-DCs were treated with activin A (100 ng/ml) for the indicated times, after which phosphorylated (upper) and total (lower) Smad2 were detected by immunoblotting. In c, HUVE-DCs were transfected with AdCMV-Smad7 (panels 1 and 2) or AdCMV-LacZ (panels 3 and 4), after which they were left untreated (panels 1 and 3) or exposed to activin A (100 ng/ml) for 1 h (panels 2 and 4). The cells were then fixed, and subcellular localization of Smad2 was detected using anti-Smad2 monoclonal antibody and a fluorescently labeled secondary antibody. The scale bar = 10 µm. d, inhibition of SMC marker expression by overexpression of Smad7. HUVE-DCs were infected with AdCMV-Smad7 or AdCMV-LacZ and then cultured for 5 days in FGF-1-free medium containing activin A (100 ng/ml). Expression of mRNAs encoding SMC and EC markers was examined by semiquantitative RT-PCR/Southern blot analyses. In e, inhibition of SMC differentiation by overexpression of Smad7. HUVE-DCs were infected with AdCMV-Smad7 (panels 1 and 3) or AdCMV-LacZ (panels 2 and 4) and cultured in FGF-1-free medium containing activin A (100 ng/ml) for 7 days. Phase-contrast (1 and 2) and fluorescent (3 and 4) micrographs of the cells double-immunostained for anti-vWF (red) and basic calponin (green) are shown. The scale bar = 50 µm.

Finally, because some TGF-beta family members, i.e. TGF-beta 1 and TGF-beta 3, have been shown to induce expression of SMC markers in bovine aortic ECs (8) and mesenchymal cells (10), we examined the effects of neutralizing anti-TGF-beta 1, -beta 2,and -beta 3 antibody on the expression of SMC marker genes. We found that the antibody did not significantly affect expression of these genes, nor did direct addition of TGF-beta 1 (16 ng/ml) or BMP-4 (50 ng/ml) to the cultures (data not shown).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have shown that, although HUVE-DCs cultured with FGF-1 constitute a population of ECs, when deprived of FGF-1, a significant fraction will differentiate into cells that fulfill many of the criteria used to define SMCs and that Smad-dependent activin A signaling is responsible for this differentiation. Because a more detailed comparison of these differentiated HUVE-DCs and SMCs obtained from the walls of the blood vessels is yet to be conducted, we are tentatively designating these cells as SMC-like. Still, this is the first study to clearly demonstrate that ECs obtained from a normal human vascular tube can differentiate into SMC-like cells identified not only by biochemical markers but also by their ability to contract in response to ET-1 and that SMC-like differentiation and dedifferentiation are reciprocally controlled by activin A and FGF-1.

It was notable that expression of activin A, follistatin, and Smad7 was all up-regulated in the HUVE-DCs after FGF-1 deprivation and that the up-regulation was reversed by administration of FGF-1. Since activin A reportedly induces expression of Smad7 and follistatin mRNA (37, 42), we suggest that activin A signaling would tend to suppress differentiation through a negative feedback mechanism involving follistatin and Smad7, although obviously this effect is not sufficient to completely inhibit activin A-induced differentiation of HUVE-DCs into SMC-like cells when FGF-1 was not present. The signaling pathway downstream of the FGF receptors involves tyrosine kinase-mediated activation of the FGF receptor and subsequent phosphorylation of various signaling molecules, including p38, phosphatidylinositol 3-kinase, and MEK (43-49). We are currently investigating which of these mediators are important for inhibition of differentiation of HUVE-DCs into SMC-like cells.

It is unclear whether it is appropriate to describe the induction of SMC-like cells from HUVE-DCs as transdifferentiation. Although HUVE-DCs maintained with FGF are widely studied as normal human endothelial cells, their differentiated characteristics become better defined when they are deprived of FGF for a short period; for example, FGF-deprived HUVECs readily form tube-like structures on extracellular matrix.2 Indeed, in the present study, removal of FGF transiently enhanced expression of vWF in cells that were negative for SMC markers. Thus, HUVE-DCs cultured in the presence of FGF may be "immature" ECs with the capacity to differentiate into "mature" ECs or to transdifferentiate into SMC-like cells. In this regard, our finding that a small fraction of the cells simultaneously expressed vWF and basic calponin suggests that expression of endothelial- and smooth muscle-specific antigens are at least not mutually exclusive.

It would also be interesting to know whether ECs derived from human adult blood vessels harbor the same potential to differentiate into SMC-like cells as do HUVE-DCs. We therefore examined the potential of HPAECs to differentiate into SMC-like cells and found that, indeed, HPAECs cultured for 1-3 weeks in the absence of FGF-1 showed increased expression of mRNAs for prostaglandin E synthase, basic calponin, and SM22alpha , although the increases were more modest than were seen in HUVE-DCs (data not shown). These results strongly suggest that ECs derived from adult human blood vessels also retain the potential to differentiate into SMC-like cells. To clarify this issue, however, more detailed investigation, including characterization of cell differentiation at the single cell level, will be essential.

Also necessary is a more detailed characterization of the SMC-like cells differentiated from HUVE-DCs. Although we found that differentiated HUVE-DCs were less responsive to ET-1 than HPASMCs, our findings may simply reflect the fact that only a small proportion of these cells were SMC-like; among rapidly differentiating HUVE-DCs, including CL14 cells, approximately one-fifth (11-23%) expressed basic calponin after 2 weeks of FGF deprivation. Alternatively, it is also possible that, at the single cell level, SMC-like cells derived from HUVE-DCs are not truly SMCs. A line of study addressing this question is currently under way.

    ACKNOWLEDGEMENTS

We thank Dr. Makiko Fujii at the Department of Biochemistry, The Center Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan and Dr. Atsuhito Nakao at the Allergy Research Center, Juntendo University School of Medicine, Tokyo, Japan for AdCMV-Smad7, and we thank Dr. Peter ten Dijke at the Division of Cellular Biochemistry, The Netherlands Cancer Institute, Amsterdam, Netherlands for anti-phosphorylated smad2 antibody.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ These authors contributed equally to this work.

|| To whom correspondence should be addressed: Age Dimension Research Center, National Institute of Advanced Industrial Science and Technology (AIST), Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8566, Japan. Tel.: 81-298-61-6504; Fax: 81-298-61-6149; E-mail: imamura-toru@aist.go.jp.

Published, JBC Papers in Press, November 1, 2002, DOI 10.1074/jbc.M207329200

2 A. Ishisaki and T. Imamura, unpublished observation.

    ABBREVIATIONS

The abbreviations used are: EC, endothelial cell; SMC, smooth muscle cell; FGF, fibroblast growth factor; TGF, transforming growth factor; PDGF, platelet-derived growth factor; HUVE-DC, human umbilical vein endothelium-derived cells; HUVEC, human umbilical vein ECs; HPAECs, human adult pulmonary artery endothelial cells; HPASMCs, human adult pulmonary artery smooth muscle cells; BMP, bone morphogenetic protein; ET, endothelin; ET-R, endothelin receptor; vWF, von Willebrand factor; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; RT, reverse transcriptase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Carmeliet, P. (2000) Nat. Med. 6, 389-395[CrossRef][Medline] [Order article via Infotrieve]
2. Hellstrom, M., Kalén, M., Lindahl, P., Abramsson, A., and Betsholtz, C. (1999) Development 126, 3047-3055[Abstract/Free Full Text]
3. Hirschi, K. K., Rohovsky, S. A., and D'Amore, P. A. (1998) J. Cell Biol. 141, 805-814[Abstract/Free Full Text]
4. Poole, T. J., Finkelstein, E. B., and Cox, C. M. (2001) Dev. Dyn. 220, 1-17[CrossRef][Medline] [Order article via Infotrieve]
5. Cox, C. M., and Poole, T. J. (2000) Dev. Dyn. 218, 371-382[CrossRef][Medline] [Order article via Infotrieve]
6. Raffi, S. (2000) J. Clin. Invest. 105, 17-19[Free Full Text]
7. Isner, J. M., and Asahara, T. (1999) J. Clin. Invest. 103, 1231-1236[Free Full Text]
8. Arciniegas, E., Sutton, A. B., Allen, T. D., and Schor, A. M. (1992) J. Cell Sci. 103, 521-529[Abstract/Free Full Text]
9. DeRuitar, M. C., Poelmann, R. E., VanMunsteren, J. C., Mironov, V., Markwald, R. R., and Gittenberger-de Groot, A. C. (1997) Circ. Res. 80, 444-451[Abstract/Free Full Text]
10. Nakajima, Y., Mironov, V., Yamagishi, T., Nakamura, H., and Markward, R. R. (1997) Dev. Dyn. 209, 296-309[CrossRef][Medline] [Order article via Infotrieve]
11. Frid, M. G., Kale, V. A., and Stenmark, K. R. (2002) Circ. Res. 90, 1189-1196[Abstract/Free Full Text]
12. Yamashita, J., Itoh, H., Hirashima, M., Ogawa, M., Nishikawa, S., Yurugi, T., Naito, M., Nakao, K., and Nishikawa, S. (2000) Nature 408, 92-96[CrossRef][Medline] [Order article via Infotrieve]
13. Araki, S., Shimada, Y., Kaji, K., and Hayashi, H. (1990) Biochem. Biophys. Res. Commun. 168, 1194-1200[Medline] [Order article via Infotrieve]
14. Garfinkel, S., Hu, X., Prudovsky, I. A., McMahon, G. A., Kapnik, E. M., McDowell, S. D., and Maciag, T. (1996) J. Cell Biol. 134, 783-791[Abstract]
15. Imamura, T., and Mitsui, Y. (1987) Exp. Cell Res. 172, 92-100[Medline] [Order article via Infotrieve]
16. Imamura, T., Engleka, K., Zhan, X., Tokita, Y., Frough, R., Roeder, D., Jackson, A., Maier, J. A., Hla, T., and Maciag, T. (1990) Science 249, 1567-1570[Medline] [Order article via Infotrieve]
17. Persson, U., Izumi, H., Souchelnyskyi, S., Itoh, S., Grimsby, S., Engström, U., Heldin, C.-H., Funa, K., and ten Dijke, P. (1998) FEBS Lett. 434, 83-87[CrossRef][Medline] [Order article via Infotrieve]
18. Nakao, A., Afrakhte, M., Moren, A., Nakayama, T., Christian, J. L., Heuchel, R., Itoh, S., Kawabata, M., Heldin, N.-E., Heldin, C.-H., and ten Dijke, P. (1997) Nature 389, 631-635[CrossRef][Medline] [Order article via Infotrieve]
19. Fujii, M., Takeda, K., Imamura, T., Aoki, H., Sampath, T. K., Enomoto, S., Kawabata, M., Kato, M., Ichijo, H., and Miyazono, K. (1999) Mol. Biol. Cell 10, 3801-3813[Abstract/Free Full Text]
20. Nakao, A., Fujii, M., Matsumura, R., Kumano, K., Saito, Y., Miyazono, K., and Iwamoto, I. (1999) J. Clin. Invest. 104, 5-11[Abstract/Free Full Text]
21. Ozawa, K., Seo, M., and Imamura, T. (1997) Brain Res. Protoc. 1, 211-216[CrossRef][Medline] [Order article via Infotrieve]
22. McComb, R. D., Jones, T. R., Pizzo, S. V., and Bigner, D. D. (1982) Acta Neuropathol (Berl.) 56, 207-213[Medline] [Order article via Infotrieve]
23. Littele, D., Said, J. W., Siegel, R. J., Fealy, M., and Fishbein, M. C. (1986) J. Pathol. 149, 89-95[Medline] [Order article via Infotrieve]
24. Jinga, V. V., Gafencu, A., Antohe, F., Constantinescu, E., Heltianu, C., Raicu, M., Manolescu, I., Hunziker, W., and Simionescu, M. (2000) Placenta 21, 325-336[CrossRef][Medline] [Order article via Infotrieve]
25. Rood, P. M., Calafat, J., von dem Borne, A. E., Gerritsen, W. R., and van der Schoot, C. E. (2000) Eur. J. Clin. Invest. 30, 618-629[CrossRef][Medline] [Order article via Infotrieve]
26. Takahashi, K., and Nadal-Ginard, B. (1991) J. Biol. Chem. 266, 13284-13288[Abstract/Free Full Text]
27. Strasser, P., Gimona, M., Moessler, H., Herzog, M., and Small, J. B. (1993) FEBS Lett. 330, 13-18[CrossRef][Medline] [Order article via Infotrieve]
28. Duband, J. L., Gimona, M., Scatena, M., Sartore, S., and Small, J. B. (1993) Differentiation 55, 1-11[Medline] [Order article via Infotrieve]
29. Lazard, D., Sastre, X., Frid, M. G., Glukhova, M. A., Thiery, J. P., and Koteliansky, V. E. (1993) Proc. Natl. Sci. U. S. A. 90, 999-1003[Abstract]
30. Weissberg, P. L., Cary, N. R., and Shanahan, C. M. (1995) Blood Press. Suppl. 2, 68-73[Medline] [Order article via Infotrieve]
31. Sobue, K., Hayashi, K., and Nishida, W. (1999) Mol. Cell. Biochem. 190, 105-118[CrossRef][Medline] [Order article via Infotrieve]
32. Soler, M., Camacho, M., Escudero, J-R., Iñiguez, M. A., and Vila, L. (2000) Circ. Res. 87, 504-507[Abstract/Free Full Text]
33. Taddei, S., Virdis, A., Ghiadoni, L., Sudano, I., Magagna, A., and Saivetti, A. (2001) Heart Failure Rev. 6, 277-285[Medline] [Order article via Infotrieve]
34. Kozian, D. H., Ziche, M., and Augstin, H. G. (1997) Lab. Invest. 76, 267-276[Medline] [Order article via Infotrieve]
35. Nakamura, T., Takio, K., Eto, Y., Shibai, H., Titani, K., and Sugino, H. (1990) Science 247, 836-838[Medline] [Order article via Infotrieve]
36. Michel, U., Farnworth, P., and Findly, J. K. (1993) Mol. Cell. Endocrinol. 91, 1-11[CrossRef][Medline] [Order article via Infotrieve]
37. Bartholin, L., Maguer-Satta, V., Hayette, S., Martel, S., Gadoux, M., Corbo, L., Magaud, J. P., and Rimokh, R. (2002) Oncogene 21, 2227-2235[CrossRef][Medline] [Order article via Infotrieve]
38. Heldin, C.-H., Miyazono, K., and ten Dijke, P. (1997) Nature 390, 465-471[CrossRef][Medline] [Order article via Infotrieve]
39. Massague, J. (1998) Annu. Rev. Biochem. 67, 753-791[CrossRef][Medline] [Order article via Infotrieve]
40. Kawabata, M., and Miyazono, K. (1999) J. Biochem. (Tokyo) 125, 9-16[Abstract]
41. Itoh, S., Itoh, F., Goumans, M. J., and ten Dijke, P. (2000) Eur. J. Biochem. 267, 6954-6967[Abstract/Free Full Text]
42. Ishisaki, A., Yamato, K., Hashimoto, S., Nakao, A., Tamaki, K., Nonaka, K., ten Dijke, P., Sugino, H., and Nishihara, T. (1999) J. Biol. Chem. 274, 13637-13642[Abstract/Free Full Text]
43. Friesel, R. E., and Maciag, T. (1995) FASEB J. 9, 919-925[Abstract/Free Full Text]
44. Harris, V. K., Coticchia, C. M., Kagan, B. L., Ahmad, S., Wellstein, A., and Riegel, A. T. (2000) J. Biol. Chem. 275, 10802-10811[Abstract/Free Full Text]
45. Debiais, F., Lemonnier, J., Hay, E., Delannoy, P., Caverzasio, J., and Marie, P. J. (2001) J. Cell. Biochem. 81, 68-81[CrossRef][Medline] [Order article via Infotrieve]
46. Carballada, R., Yasuo, H., and Lemaire, P. (2001) Development 128, 35-44[Abstract/Free Full Text]
47. Hadari, Y. R., Gotoh, N., Kouhara, H., Lax, I., and Schlessinger, J. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 8578-8583[Abstract/Free Full Text]
48. Giuliani, R., Bastaki, M., Coltrini, D., and Presta, M. (1999) J. Cell Sci. 112, 2597-2606[Abstract/Free Full Text]
49. Tokuda, H., Kozawa, O., and Uematsu, T. (2000) J. Bone Miner. Res. 15, 2371-2379[Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.